Matthew Hawryluk - May 15, 2024 Form 4 Insider Report for Gritstone bio, Inc. (GRTS)

Role
EVP, CHIEF BUSINESS OFFICER
Signature
/s/ Vassiliki Economides, Attorney-in-Fact for Matthew Hawryluk
Stock symbol
GRTS
Transactions as of
May 15, 2024
Transactions value $
-$6,929
Form type
4
Date filed
5/17/2024, 09:56 PM
Previous filing
Apr 12, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction GRTS Common Stock Award $0 +19.1K +6.3% $0.00 323K May 15, 2024 Direct F1, F2
transaction GRTS Common Stock Sale -$6.93K -9.26K -2.86% $0.75 314K May 16, 2024 Direct F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction GRTS Stock Option (Right to Buy) Award $0 +180K $0.00 180K May 15, 2024 Common Stock 180K $0.75 Direct F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents Performance Stock Units ("PSUs") granted on March 22, 2024 that were earned by the Reporting Person as a result of the achievement of certain performance criteria as certified by the Issuer's Board of Directors on May 15, 2024. The PSUs vest over one year; 1/2 vested on May 15, 2024, and thereafter the remaining 1/2 will vest on May 15, 2025, subject to the continuing service of the Reporting Person on such vesting date. Each PSU represents a contingent right to receive one share of the Issuer's Common Stock.
F2 Includes 273,719 Restricted Stock Units ("RSUs") and PSUs which are subject to vesting.
F3 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of PSUs.
F4 The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.735 to $0.7616 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F5 The option vests as to 1/2 of the total grant on September 30, 2024, with the remainder of grant vesting on September 30, 2025, subject to the continued service of the Reporting Person on each vesting date.